Central Venous Catheter Removal After Hematopoietic Stem Cell Transplant: A Review and Perspective
- 24 November 2025
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (3) , e70001
Abstract
Central venous catheters (CVCs) are a cornerstone of hematopoietic stem cell transplantation (HSCT), facilitating the delivery of chemotherapy, parenteral nutrition, medications, and blood products. Despite CVCs’ essential role, prolonged use can lead to complications such as increased risk of infection, thrombosis, mechanical issues, and psychosocial burden. However, the timing of CVC removal remains highly variable across institutions. Additionally, there are no standardized guidelines to balance the benefits of extended access against the risks of prolonged use. This narrative review examines the existing literature on CVC management post‐HSCT, highlighting key factors influencing the removal timing, such as patient characteristics, disease‐specific considerations, and institutional practices. The review emphasizes the urgent need for multi‐institutional research and standardized protocols to improve outcomes, reduce complications, and enhance the quality of care for HSCT patients.Keywords
This publication has 33 references indexed in Scilit:
- Preventing central line-associated bloodstream infections: A position paper of the International Society for Infectious Diseases, 2024 updateInternational Journal of Infectious Diseases, 2024
- Results of a long‐term, prospective study on complications of central venous catheter in pediatric patients with hematologic‐oncologic diseasesPediatric Blood & Cancer, 2024
- Vascular access device type for systemic anti-cancer therapies in cancer patients: A scoping reviewCritical Reviews in Oncology/Hematology, 2024
- Scheduled removal of central venous catheters (CVC) to prevent CVC-related bloodstream infections in patients with hematological disease or autologous stem cell transplantation: a registry-based randomized simulation-studyAnnals of Hematology, 2022
- Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell TransplantJAMA Network Open, 2020
- Outcomes after bloodstream infection in hospitalized pediatric hematology/oncology and stem cell transplant patientsPediatric Blood & Cancer, 2019
- Psychological interventions for needle-related procedural pain and distress in children and adolescentsCochrane Database of Systematic Reviews, 2018
- Defining Incidence and Risk Factors for Catheter-Associated Bloodstream Infections in an Outpatient Adult Hematopoietic Cell Transplantation ProgramTransplantation and Cellular Therapy, 2018
- Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2016
- Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell TransplantationTransplantation and Cellular Therapy, 2016